Linked Life Data

16912056

Source:http://linkedlifedata.com/resource/pubmed/id/16912056

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-1-4
pubmed:abstractText
Several hormones that regulate nutritional status also impact on bone metabolism. Preptin is a recently isolated 34-amino acid peptide hormone that is cosecreted with insulin and amylin from the pancreatic beta-cells. Preptin corresponds to Asp(69)-Leu(102) of pro-IGF-II. Increased circulating levels of a pro-IGF-II peptide complexed with IGF-binding protein-2 have been implicated in the high bone mass phenotype observed in patients with chronic hepatitis C infection. We have assessed preptin's activities on bone. Preptin dose-dependently stimulated the proliferation (cell number and DNA synthesis) of primary fetal rat osteoblasts and osteoblast-like cell lines at periphysiological concentrations (>10(-11) M). In addition, thymidine incorporation was stimulated in murine neonatal calvarial organ culture, likely reflecting the proliferation of cells from the osteoblast lineage. Preptin did not affect bone resorption in this model. Preptin induced phosphorylation of p42/p44 MAP kinases in osteoblastic cells in a dose-dependent manner (10(-8)-10(-10) M), and its proliferative effects on primary osteoblasts were blocked by MAP kinase kinase inhibitors. Preptin also reduced osteoblast apoptosis induced by serum deprivation, reducing the number of apoptotic cells by >20%. In vivo administration of preptin increased bone area and mineralizing surface in adult mice. These data demonstrate that preptin, which is cosecreted from the pancreatic beta-cell with amylin and insulin, is anabolic to bone and may contribute to the preservation of bone mass observed in hyperinsulinemic states such as obesity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0193-1849
pubmed:author
pubmed:issnType
Print
pubmed:volume
292
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
E117-22
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:16912056-Animals, pubmed-meshheading:16912056-Bone Development, pubmed-meshheading:16912056-Cell Differentiation, pubmed-meshheading:16912056-Cell Proliferation, pubmed-meshheading:16912056-Cell Survival, pubmed-meshheading:16912056-Cells, Cultured, pubmed-meshheading:16912056-Humans, pubmed-meshheading:16912056-Insulin-Like Growth Factor II, pubmed-meshheading:16912056-Insulin-Secreting Cells, pubmed-meshheading:16912056-Male, pubmed-meshheading:16912056-Mice, pubmed-meshheading:16912056-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:16912056-Mitogen-Activated Protein Kinase 3, pubmed-meshheading:16912056-Osteoblasts, pubmed-meshheading:16912056-Osteoclasts, pubmed-meshheading:16912056-Osteogenesis, pubmed-meshheading:16912056-Peptide Fragments, pubmed-meshheading:16912056-Peptides, pubmed-meshheading:16912056-Pertussis Toxin, pubmed-meshheading:16912056-Rats, pubmed-meshheading:16912056-Receptors, Islet Amyloid Polypeptide, pubmed-meshheading:16912056-Receptors, Peptide, pubmed-meshheading:16912056-Swiss 3T3 Cells
pubmed:year
2007
pubmed:articleTitle
Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo.
pubmed:affiliation
Dept. of Medicine, Univ. of Auckland, Private Bag 92019, Auckland, NZ, USA. j.cornish@auckland.ac.nz
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Evaluation Studies